Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study

Author： Persson Frederik   Rossing Peter   Hovind Peter   Stehouwer Coen   Schalkwijk Casper   Tarnow Lise   Parving Hans-Henrik  

Publisher： Informa Healthcare

ISSN： 0036-5513

Source： Scandinavian Journal of Clinical and Laboratory Investigation, Vol.68, Iss.8, 2008-01, pp. : 731-738

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Increased urinary orosomucoid excretion: a proposed marker for inflammation and endothelial dysfunction in patients with type 2 diabetes

By Christiansen M. S.   Iversen K.   Larsen C. T.   Goetze J. P.   Hommel E.   Mølvig J.   Pedersen B. K.   Magid E.   Feldt-Rasmussen B.  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 69, Iss. 2, 2009-04 ,pp. : 272-281

Informa Healthcare

Access to resources Recommend Favorite

Proximal Tubule Dysfunction Is Dissociated from Endothelial Dysfunction in Normoalbuminuric Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

By  

Nephron Clin Pract, Vol. 118, Iss. 2, 2010-12 ,pp. : c155-c164

Karger

Access to resources Recommend Favorite

Association of Metabolic Syndrome with Microalbuminuria in Non-Hypertensive Type 2 Diabetic Patients

By  

Nephron Clin Pract, Vol. 106, Iss. 3, 2007-05 ,pp. : c98-c103

Karger

Access to resources Recommend Favorite

Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 31, Iss. 6, 2015-09 ,pp. : 572-581

John Wiley & Sons Inc

Access to resources Recommend Favorite

Serum Levels of the Advanced Glycation End Products Nε-Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension

By  

Nephron Clin Pract, Vol. 108, Iss. 4, 2008-04 ,pp. : c291-c297

Karger

Access to resources Recommend Favorite